vatalanib has been researched along with tipifarnib in 2 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 309 | 92 | 94 |
| Protein | Taxonomy | vatalanib (IC50) | tipifarnib (IC50) |
|---|---|---|---|
| Chain B, Protein farnesyltransferase beta subunit | Rattus norvegicus (Norway rat) | 0.0007 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 2.88 | |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Bos taurus (cattle) | 0.5503 | |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Homo sapiens (human) | 2.2237 | |
| Protein farnesyltransferase subunit beta | Bos taurus (cattle) | 0.0006 | |
| Protein farnesyltransferase subunit beta | Homo sapiens (human) | 0.0019 | |
| Geranylgeranyl transferase type-1 subunit beta | Homo sapiens (human) | 10 | |
| Geranylgeranyl transferase type-1 subunit beta | Bos taurus (cattle) | 1.1 | |
| Protein farnesyltransferase alpha subunit | Plasmodium falciparum (malaria parasite P. falciparum) | 0.017 | |
| CAAX farnesyltransferase subunit beta | Plasmodium falciparum (malaria parasite P. falciparum) | 0.017 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borner, MM | 1 |
| Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN | 1 |
2 review(s) available for vatalanib and tipifarnib
| Article | Year |
|---|---|
[Molecular targets in colon cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolones; Receptors, Platelet-Derived Growth Factor; Receptors, Somatomedin; Signal Transduction; Sirolimus; Sunitinib | 2006 |
[Problems in the current target therapy of malignancies].
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab | 2005 |